{
    "doi": "https://doi.org/10.1182/blood.V104.11.4896.4896",
    "article_title": "IgA and IgG Hypogammaglobulinemia Persists in Most Patients with Waldenstrom\u2019s Macroglobulinemia Despite Therapeutic Responses, Including Complete Remissions. ",
    "article_date": "November 16, 2004",
    "session_type": "Abstracts Not Selected for Presentation",
    "abstract_text": "Recurrent infections are common in pts with Waldenstrom\u2019s macroglobulinemia (WM) and may be related to IgA and IgG hypogammaglobulinemia. The impact of therapy and therapeutic responses on humoral immunity in WM is therefore of clinical interest. We examined IgA and IgG levels before and after therapy in 92 serially treated and responding WM patients. Their median age was 59 yrs and 70/92 (76.1%) were previously untreated. Median follow-up for all patients was 11 (range 3-134) months. Pre-therapy, 72/92 (78.2%) and 70/92 (76.1%), and post-therapy 82/92 (89.1%) and 80/92 (86.9%) pts demonstrated IgG (<700 mg/dL) and IgA (<70 mg/dL) hypogammaglobulinemia, respectively. Changes in median IgG and IgA levels by therapy were as follows:  . N= . Pre-IgG . Post-IgG . T-Test . Pre-IgA . Post-IgA . T-Test . Nucleoside analogue 5 438 399 0.63 32 38 0.35 Rituximab 17 455 358 0.29 35 29 0.43 Rituximab/Thalidomide 19 388 374 0.3 28 24 0.32 Rituximab/Nucleoside 21 571 423 0.006 55 29 0.05 CHOP 3 702 568 0.62 48 30 0.82 CHOP/Rituximab 14 537 383 0.1 61 36 0.21 Chlorambucil \u00b1 steroids 5 837 659 0.57 129 66 0.52 Campath-1H 7 521 444 0.62 28 27 0.61 HD Dexamethasone 1 269 173 NA 27 28 NA All therapies  92  480  398  0.008  38  28  0.01  . N= . Pre-IgG . Post-IgG . T-Test . Pre-IgA . Post-IgA . T-Test . Nucleoside analogue 5 438 399 0.63 32 38 0.35 Rituximab 17 455 358 0.29 35 29 0.43 Rituximab/Thalidomide 19 388 374 0.3 28 24 0.32 Rituximab/Nucleoside 21 571 423 0.006 55 29 0.05 CHOP 3 702 568 0.62 48 30 0.82 CHOP/Rituximab 14 537 383 0.1 61 36 0.21 Chlorambucil \u00b1 steroids 5 837 659 0.57 129 66 0.52 Campath-1H 7 521 444 0.62 28 27 0.61 HD Dexamethasone 1 269 173 NA 27 28 NA All therapies  92  480  398  0.008  38  28  0.01  View Large Changes in median IgG and IgA levels by response category were as follows:  . N= . Pre-IgG . Post-IgG . T-Test . Pre-IgA . Post-IgA . T-Test . CR 8 644 472 0.05 75 37 0.08 PR 70 415 349 0.09 27 28 0.91 MR 14 474 394 0.01 38 26 0.02 . N= . Pre-IgG . Post-IgG . T-Test . Pre-IgA . Post-IgA . T-Test . CR 8 644 472 0.05 75 37 0.08 PR 70 415 349 0.09 27 28 0.91 MR 14 474 394 0.01 38 26 0.02 View Large These studies demonstrate that IgA and IgG hypogammaglobulinemia persists despite therapeutic responses, including complete remissions in patients with WM. Futhermore, the therapeutic regimen employed may aggravate persistent IgA and IgG hypogammaglobulinemia.",
    "topics": [
        "disease remission",
        "hypogammaglobulinemia",
        "immunoglobulin a",
        "immunoglobulin g",
        "waldenstrom macroglobulinemia",
        "rituximab",
        "brachial plexus neuritis",
        "cyclophosphamide, doxorubicin, prednisone, and vincristine",
        "alemtuzumab",
        "chlorambucil"
    ],
    "author_names": [
        "Steven Treon",
        "Andrew Branagan",
        "Zachary Hunter",
        "Daniel Ditzel Santos",
        "Olivier Tournilhac",
        "Evdoxia Hatjiharissi",
        "Lian Xu",
        "Robert Manning"
    ],
    "author_dict_list": [
        {
            "author_name": "Steven Treon",
            "author_affiliations": [
                "Bing Program for Waldenstrom\u2019s Macroglobulinemia, Dana Farber Cancer Institute",
                "Harvard Medical School, Boston, MA, USA"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Andrew Branagan",
            "author_affiliations": [
                "Bing Program for Waldenstrom\u2019s Macroglobulinemia, Dana Farber Cancer Institute"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Zachary Hunter",
            "author_affiliations": [
                "Bing Program for Waldenstrom\u2019s Macroglobulinemia, Dana Farber Cancer Institute"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Daniel Ditzel Santos",
            "author_affiliations": [
                "Bing Program for Waldenstrom\u2019s Macroglobulinemia, Dana Farber Cancer Institute",
                "Harvard Medical School, Boston, MA, USA"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Olivier Tournilhac",
            "author_affiliations": [
                "Bing Program for Waldenstrom\u2019s Macroglobulinemia, Dana Farber Cancer Institute",
                "Harvard Medical School, Boston, MA, USA"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Evdoxia Hatjiharissi",
            "author_affiliations": [
                "Bing Program for Waldenstrom\u2019s Macroglobulinemia, Dana Farber Cancer Institute",
                "Harvard Medical School, Boston, MA, USA"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lian Xu",
            "author_affiliations": [
                "Bing Program for Waldenstrom\u2019s Macroglobulinemia, Dana Farber Cancer Institute"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Robert Manning",
            "author_affiliations": [
                "Bing Program for Waldenstrom\u2019s Macroglobulinemia, Dana Farber Cancer Institute"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-04-22T03:09:53",
    "is_scraped": "1"
}